Logo image
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
Journal article   Open access   Peer reviewed

Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial

Nicholas A. Vitanza, Rebecca Ronsley, Michelle Choe, Kristy Seidel, Wenjun Huang, Stephanie D. Rawlings-Rhea, Madison Beam, Leonel Steinmetzer, Ashley L. Wilson, Christopher Brown, …
Nature Medicine, Vol.31(3)
2025

Abstract

Adolescent B7 Antigens Brain Stem Neoplasms Child Child, Preschool Diffuse Intrinsic Pontine Glioma Female Glioma Humans Immunotherapy, Adoptive Male Receptors, Chimeric Antigen T-Lymphocytes B7 antigen CD276 protein, human chimeric antigen receptor abdominal pain adult agitation anorexia Article backache chimeric antigen receptor T-cell immunotherapy clinical article clinical outcome diplopia dizziness dysarthria dysphagia dyspnea facial nerve disease fatigue fever headache hiccup human hydrocephalus hypotension lymphocytopenia malaise muscle weakness nausea neck pain paresthesia peripheral neuropathy phase 1 clinical trial photophobia pontine glioma prepontine cistern pruritus survival T1 weighted imaging T2 weighted imaging tremor trochlear nerve disease tumor bleeding urine incontinence vomiting adoptive immunotherapy adverse event brain stem tumor clinical trial preschool child procedures T lymphocyte therapy transplantation Ataxia Hypertension Immunotherapy Pain Immunology Pathology
Diffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor that confers a median survival of 11 months. As B7-H3 is expressed on pediatric CNS tumors, we conducted BrainChild-03, a single-center, dose-escalation phase 1 clinical trial of repetitive intracerebroventricular (ICV) dosing of B7-H3-targeting chimeric antigen receptor T cells (B7-H3 CAR T cells) for children with recurrent or refractory CNS tumors and DIPG. Here we report results from Arm C, restricted to patients with DIPG. The primary objectives were to assess feasibility and tolerability, which were both met. Secondary objectives included assessments of CAR T cell distribution and survival. A total of 23 patients with DIPG enrolled, and 21 were treated with repeated doses of ICV B7-H3 CAR T cells using intra-patient dose-escalation regimens without previous lymphodepletion. Concurrent tumor-directed therapy, including re-irradiation, was not allowed while on protocol therapy. We delivered a total of 253 ICV doses and established the highest planned dose regimen, DR4, which escalated up to 10 × 107 cells per dose, as the maximally tolerated dose regimen. Common adverse events included headache, fatigue and fever. There was one dose-limiting toxicity (intratumoral hemorrhage) during DR2. For all treated patients (n = 21), the median survival from their initial CAR T cell infusion was 10.7 months and the median survival from diagnosis was 19.8 months with 3 patients still alive at 44, 45 and 52 months from diagnosis. Ultimately, this completed first-in-human trial shows that repetitive ICV dosing of B7-H3 CAR T cells in pediatric and young adult patients with DIPG is tolerable, including multiyear repeated dosing, and may have clinical efficacy that warrants further investigation on a multisite phase 2 trial. ClinicalTrials.gov registration: NCT04185038. © The Author(s) 2025.
url
https://doi.org/10.1038/s41591-024-03451-3View
Published (Version of record) Open

Metrics

10 Record Views

Details

Logo image